A comparison of in vivo gene delivery methods for antisense therapy in ligament healing

To determine the most efficient in vivo delivery method of oligonucleotides for antisense therapy in ligament healing, fluorescence-labelled phosphorothioate oligodeoxynuleotides (ODN) were introduced into 12 rabbit ligament scars 2 weeks after injury using haemagglutinating virus of Japan (Sendai virus; HVJ)-conjugated liposomes. We compared the efficiency of cellular uptake of fluorescence as a percentage of all cells in each scar using three delivery procedures: (1) direct free-hand injection into the ligament scar using a conventional syringe; (2) systematic direct scar injection using a repeating 10 μl dispenser and a square mesh grid system; and (3) injection into the feeding (femoral) artery. Results showed that there was a significant difference in fluorescence uptake by scar cells on day 1 after injection between the three delivery methods: (1) direct free-hand, 9.7 ± 7.6% (average ± s.d.); (2) systematic direct, 58.4 ± 15.9%; and (3) intra-arterial, 0.2 ± 0.1%. Systematic direct injection was most efficient and it resulted in 25.9 ± 13.0% of scar cells being labeled at 7 days after transfection. We then introduced antisense ODN for the rabbit proteoglycan, decorin, into ligament scars with this delivery method and confirmed a significant inhibition of decorin mRNA expression in antisense-treated scar tissues in vivo both at 2 days (42.3 ± 14.7% of sense control ± s.d.; P < 0.0025) and 3 weeks (60.5 ± 28.2% of sense control ± s.d.; p < 0.024) after treatment, compared with sense odn-treated scars. decorin was significantly suppressed also at protein level in antisense-treated scars at 4 weeks (66.6 ± 35.7% of sense control ± s.d.; p < 0.045) after treatment. these results demonstrate that in vivo transfection efficiency in ligament scars is ‘delivery system dependent’ and that introduction of antisense odn for the small proteoglycan, decorin, with this delivery method can lead to significant suppression of its expression over 3 weeks both at mrna and protein levels. thus, an effective model for the potential manipulation of scar composition and quality in ligament healing has been established.

[1]  M. Aoki,et al.  Adenovirus‐mediated gene transfer into tendon and tendon sheath , 1996, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[2]  R. Rangayyan,et al.  Quantitative analysis of the fine vascular anatomy of articular ligaments , 1992, IEEE Transactions on Biomedical Engineering.

[3]  P. Robbins,et al.  Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. , 1996, Gene therapy.

[4]  C. Frank.  Soft tissue healing , 1994 .

[5]  M. Nakanishi,et al.  Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method. , 1991, The Journal of biological chemistry.

[6]  C. Frank,et al.  Rapid isolation of total RNA from small samples of hypocellular, dense connective tissues. , 1997, BioTechniques.

[7]  T Ochi,et al.  Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament , 1998, Gene Therapy.

[8]  K. Kaufman,et al.  Fate of the ACL-injured Patient , 1994, The American journal of sports medicine.

[9]  A. Malmström,et al.  Differential expressions of mRNA for proteoglycans, collagens and transforming growth factor-beta in the human cervix during pregnancy and involution. , 1998, Biochimica et biophysica acta.

[10]  D. Heinegård,et al.  Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. , 1984, The Biochemical journal.

[11]  K. Miyasaka.  The incidece of knee ligament injuries in the general population , 1991 .

[12]  Y. Kaneda,et al.  Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. , 1993, The Journal of clinical investigation.

[13]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[14]  Y. Okada,et al.  Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method. , 1991, Journal of Biological Chemistry.

[15]  Y. Okada,et al.  Modification of cell membranes with viral envelopes during fusion of cells with HVJ (Sendai virus). , 1975, Experimental cell research.

[16]  R. Morishita,et al.  Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[17]  C. Frank,et al.  Natural history of healing in the repaired medial collateral ligament , 1983, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[18]  Y. Kaneda,et al.  Fusigenic viral liposome for gene therapy in cardiovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Scott,et al.  Mapping the locations of the epitopes of five monoclonal antibodies to the core protein of dermatan sulfate proteoglycan II (decorin). , 1993, The Journal of biological chemistry.

[20]  Thomas A. Mustoe, MD, FACS,et al.  Growth factors and wound healing: platelet-derived growth factor as a model cytokine. , 1991, Annual review of medicine.

[21]  S L Woo,et al.  Medial collateral ligament healing , 1983, The American journal of sports medicine.

[22]  Dale M. Daniel,et al.  Knee Ligaments: Structure, Function, Injury, and Repair , 1991 .

[23]  E. Mekada,et al.  Modification of cell membranes with viral envelopes during fusion of cells with HVJ (Sendai virus). III. Effects of mono- and di-saccharides on cell fusion and membrane movement of fused cells. , 1975, Experimental cell research.

[24]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[25]  Renato V. Iozzo,et al.  Targeted Disruption of Decorin Leads to Abnormal Collagen Fibril Morphology and Skin Fragility , 1997, Journal of Cell Biology.

[26]  A. Ghahary,et al.  Immunohistochemical localization of the proteoglycans decorin, biglycan and versican and transforming growth factor‐β in human post‐burn hypertrophic and mature scars , 1995, Histopathology.

[27]  Y. Kaneda,et al.  Transient introduction of a foreign gene into healing rat patellar ligament. , 1996, The Journal of clinical investigation.